Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Janux Therapeutics Inc shares valued at $25,799 were sold by Meyer Andrew Hollman on Jan 02 ’26. At $13.73 per share, Meyer Andrew Hollman sold 1,879 shares. The insider’s holdings dropped to 83,095 shares worth approximately $1.16 million following the completion of this transaction.
Also, DiRaimondo Thomas sold 2,505 shares, netting a total of over 34,394 in proceeds. Following the sale of shares at $13.73 each, the insider now holds 124,425 shares.
Before that, Campbell David Alan had sold 8,072 shares from its account. In a trade valued at $110,829, the President and CEO traded Janux Therapeutics Inc shares for $13.73 each. Upon closing the transaction, the insider’s holdings decreased to 8,072 shares, worth approximately $3.96 million.
As published in their initiating research note from Wolfe Research on November 18, 2025, Janux Therapeutics Inc [JANX] has been a Peer perform. Analysts at Barclays started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid September. As of September 10, 2025, Truist has initiated its “Buy” rating for JANX. Earlier on September 10, 2025, Stifel initiated its rating. Their recommendation was “a Buy” for JANX stock.
Analyzing JANX Stock Performance
On last trading session, Janux Therapeutics Inc [NASDAQ: JANX] plunged -0.50% to $13.91. The stock’s lowest price that day was $13.6401, but it reached a high of $14.06 in the same session. During the last five days, there has been a surge of approximately 0.80%. Over the course of the year, Janux Therapeutics Inc shares have dropped approximately -74.00%. Shares of the company reached a 52-week high of $14.30 on 01/07/26 and a 52-week low of $13.26 on 01/06/26.
Support And Resistance Levels for Janux Therapeutics Inc (JANX)
According to the 24-hour chart, there is a support level at 13.68, which, if violated, would cause prices to drop to 13.45. In the upper region, resistance lies at 14.10. The next price resistance is at 14.29. RSI (Relative Strength Index) is 31.50 on the 14-day chart, showing neutral technical sentiment.
Is Janux Therapeutics Inc subject to short interest?
Stocks of Janux Therapeutics Inc saw a sharp rise in short interest on 2025-12-15 jumping by 0.26 million shares to 7.4 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 7.13 million shares. A jump of 3.56% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.86 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.86.
Which companies own the most shares of Janux Therapeutics Inc (JANX)?
In terms of Janux Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 51 in the next 12 months, up nearly 264.81% from the previous closing price of $13.98. Analysts anticipate Janux Therapeutics Inc stock to reach 72 by 2026, with the lowest price target being 29. In spite of this, 3 analysts ranked Janux Therapeutics Inc stock as Buy at the end of 2026. On September 04, 2025, Guggenheim assigned a price target of “a Buy” to the stock and initiated coverage with a $72.
